NCT05010876View on ClinicalTrials.gov

Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

June 13, 2021

Study Completion Date

June 21, 2021

Conditions
Covid19
Interventions
DRUG

C1 Inhibitor Human

standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units

DRUG

Icatibant Injection

a single injection of 30 mg subcutaneously

OTHER

Placebo

The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.

Trial Locations (1)

78150

Hôpital Privé de Parly II, Le Chesnay

All Listed Sponsors
lead

GCS Ramsay Santé pour l'Enseignement et la Recherche

OTHER

NCT05010876 - Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study). | Biotech Hunter | Biotech Hunter